Immunome Inc (IMNM NASDAQ) stock market data APIs
$24.1121
2.12(8.8%)
as of February 5, 2026
Try our APIs with
free plan!
Immunome Inc Financial Data Overview
Price chart is built with
Anychart
Immunome, Inc., a clinical-stage biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. Its preclinical assets include IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, including IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Prev. Close
24.1121
Open
26.2317
High
27.0861
Low
23.7424
52 wk Range
5.1501-27.65
Market Cap
2 648 M
Shares Outstanding
110 M
Revenue
9 679 K
EPS
-0.65
Beta
2.106
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Immunome Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Immunome Inc data using free add-ons & libraries
Get Immunome Inc Fundamental Data
Immunome Inc Fundamental data includes:
- Net Revenue: 9 679 K
- EBITDA: -204 563 008
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-07
- EPS/Forecast: -0.57
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Immunome Inc News
New
Is Immunome, Inc. (IMNM) The Best Booming Stock To Buy Right Now?
Immunome, Inc. (NASDAQ:IMNM) is among the 14 best booming stocks to buy right now. The company’s shares are surging and have gained 48% in the last three months.Is Immunome, Inc. (IMNM) The Best Boo...
Jim Cramer on Immunome: “If You Want to Speculate on It, Fine”
Immunome, Inc. (NASDAQ:IMNM) is one of the stocks Jim Cramer offered insights on. When a caller inquired about the stock, Cramer stated: “This company’s losing so much money, I know, but it’s D...
Immunome to Present at 44th Annual J.P. Morgan Healthcare Conference
BOTHELL, Wash., January 06, 2026--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announ...
Weekly Buzz: CYTK Scores First FDA Approval, INSM Ends Rhinosinusitis Study, XOMA Acquires GBIO
(RTTNews) - The biotech industry witnessed several key events this week, including major FDA approvals, acquisitions, pivotal clinical trial results and setbacks. • A series of FDA approvals were a...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
